Metagenomic Sequencing Market Size, Share, Analysis, Growth, Forecast 2032

Metagenomic sequencing is a powerful molecular biology technique used to study the genetic material (DNA or RNA) of entire microbial communities present in a sample taken from a particular environment. Unlike traditional sequencing methods that focus on individual organisms, metagenomic sequencing provides a comprehensive view of the genetic diversity and composition of all microorganisms in a complex ecosystem, such as a soil sample, water sample, or a biological specimen.

As of my last knowledge update in September 2021, metagenomic sequencing was a rapidly evolving field with the potential to transform our understanding of microbial communities and their impact on various environments, including human health, ecosystems, and industrial processes. While I can provide insights based on information available up to that point, it's important to note that the situation may have evolved since then.

The global metagenomic sequencing market size was evaluated at $1.99 Billion in 2023 and is slated to hit $6.21 Billion by the end of 2032.

a CAGR of nearly 13.50% between 2024 and 2032.

The current and estimated demand for regions such as Middle East & Africa, North America, Asia Pacific, Latin America and Europe is covered for metagenomic sequencing market. North America held largest share of global metagenomic sequencing market in 2018. Presence of developed research and development infrastructure, government funding, increasing public and private investment in NGS projects are some of factors that support market growth in this region. Europe held second leading position in the market due to increasing investments in next generation sequencing technologies and favorable government funding. Asia Pacific region is expected to register highest growth during the forecast period as major players are focusing on major emerging markets like India, China etc.

Major players included in the report are Thermo Fisher Scientific, Inc., Illumina, Inc., PerkinElmer, QIAGEN N.V., BGI Group, Oxford Nanopore Technologies Ltd., GENEWIZ, Eurofins Scientific, Macrogen Inc., Zymo Research Corporation, Novogene Corporation, IntegraGen SA, NuGEN Technologies, Inc., DNAStar, Inc., and Microsynth AG.